Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note released on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Trevena in a report on Thursday, November 14th.

Trevena Stock Performance

NASDAQ:TRVN opened at $1.69 on Friday. The company has a market cap of $1.46 million, a price-to-earnings ratio of -0.04 and a beta of 1.08. The stock’s fifty day moving average price is $1.76 and its two-hundred day moving average price is $3.78. Trevena has a 52-week low of $1.13 and a 52-week high of $19.23.

Trevena (NASDAQ:TRVN) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share for the quarter. The firm had revenue of $0.28 million during the quarter. On average, equities analysts predict that Trevena will post -23.04 EPS for the current fiscal year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.